Gene transfer therapy trial of Chondromodulin I for the experimental arthritis
| Project/Area Number |
14571363
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | NIIGATA UNIVERSITY |
|---|
Principal Investigator |
ARAI Katsumitsu NIIGATA UNIVERSITY, Graduate School of Medical and Dental Sciences, Assistant, 大学院・医歯学総合研究科, 助手 (60323961)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ENDO Naoto NIIGATA UNIVERSITY, Graduate School of Medical and Dental Sciences, Professor, 大学院・医歯学総合研究科, 教授 (10251810)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2003: ¥1,000,000 (Direct Cost: ¥1,000,000)
Fiscal Year 2002: ¥2,500,000 (Direct Cost: ¥2,500,000)
|
|---|
| Keywords | arthritis / Chondronodulin I / angiogenesis inhibitor / gene transfer / treatment |
|---|
| Research Abstract |
Lewis rats were injected at their both footpads with M.Butyricum(day 0). 1x10^<10>pfu virus of AxCAChM-I(Chondronodulin I recombinant Adenovirus) was injected in right knee joint and AxCALacZ(β-galactosidase recombinant Adenovirus) were injected in left knee joint at day 0,7,14,and 21. PBS was injected as same protocol in anther rats for basal control. Rats were observed daily for the onset of the arthritis, and an arthritic index was derived by grading the severity and synovitis of each knee joint.
The arthritis of knee joint was observed from day 10 to day 14. The body weight was decreased after arthritis progression.
AxCALacZ was presented in synovial tissue in injected knee joint by immnohistochemical staining. No liver injury was observed by injection into knee joint, which was also checked by immunohistochemical staining.
Progression of disease was suppressed by AxCAChM-I compared with AxCALacZ injected rats. The number of blood vessels in synovium treated with AxCAChM-I was less than treated with AxCALacZ. But the number of vessels in synovium treated with PBS was less than treated with AxCAChM-I. This is caused by immunogenicity of adenovirus vector.
Gene therapy with Chondronodulin I may be one of the useful methods for rheumatoid arthritis, but we have to change the adenoviral delivery methods for Chondronodulin I treatment.
|
Report
(3 results)
Research Products
(17 results)
